[Gastrointestinal side effects of apremilast : Characterization and management].
Gastrointestinale Beschwerden unter Apremilast : Charakterisierung und Management.
Diarrhea
Nausea
PDE4
Psoriasis
Psoriatic arthritis
Journal
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
ISSN: 1432-1173
Titre abrégé: Hautarzt
Pays: Germany
ID NLM: 0372755
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
pubmed:
3
4
2019
medline:
8
10
2019
entrez:
3
4
2019
Statut:
ppublish
Résumé
Apremilast is an oral inhibitor of phosphodiesterase-4 (PDE4) that is licensed for the second-line treatment of psoriasis and psoriatic arthritis. Data from several phase III clinical trials and real-world studies showed a good benefit-risk profile, with diarrhea and nausea as the most common adverse events. Diarrhea and nausea most frequently occurred during the first month of treatment. In most cases, they were mild or moderate in severity and tended to resolve over time with continued dosing and without intervention. In this review we summarize available data on gastrointestinal side effects of apremilast in patients with psoriasis and psoriasis arthritis and provide practical strategies for managing these symptoms.
Identifiants
pubmed: 30937481
doi: 10.1007/s00105-019-4396-6
pii: 10.1007/s00105-019-4396-6
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Phosphodiesterase 4 Inhibitors
0
Thalidomide
4Z8R6ORS6L
apremilast
UP7QBP99PN
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
354-362Références
Drug Saf. 2000 Jan;22(1):53-72
pubmed: 10647976
J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S54-71
pubmed: 12000594
J Clin Invest. 2002 Oct;110(7):1045-52
pubmed: 12370283
Physiol Rev. 2004 Jan;84(1):137-67
pubmed: 14715913
Drug Discov Today. 2005 Nov 15;10(22):1503-19
pubmed: 16257373
Biochem Pharmacol. 2012 Jun 15;83(12):1583-90
pubmed: 22257911
Ther Adv Musculoskelet Dis. 2010 Oct;2(5):271-8
pubmed: 22870453
Bioorg Med Chem Lett. 2012 Nov 15;22(22):6794-800
pubmed: 23046962
Best Pract Res Clin Gastroenterol. 2012 Oct;26(5):633-48
pubmed: 23384808
Am J Respir Cell Mol Biol. 2014 Mar;50(3):549-58
pubmed: 24106801
Ann Rheum Dis. 2014 Jun;73(6):1020-6
pubmed: 24595547
Z Gastroenterol. 2015 May;53(5):418-59
pubmed: 25965989
J Am Acad Dermatol. 2015 Jul;73(1):37-49
pubmed: 26089047
Br J Dermatol. 2015 Dec;173(6):1387-99
pubmed: 26357944
Pharmacol Res. 2015 Dec;102:107-112
pubmed: 26429773
Pharmacopsychiatry. 1989 Jul;22(4):156-60
pubmed: 2668980
Ann Rheum Dis. 2016 Jun;75(6):1065-73
pubmed: 26792812
Behav Brain Res. 2016 Apr 15;303:26-33
pubmed: 26794595
Acta Derm Venereol. 2016 May;96(4):514-20
pubmed: 26837052
Am J Gastroenterol. 2016 May;111(5):602-22
pubmed: 27068718
J Rheumatol. 2016 Sep;43(9):1724-34
pubmed: 27422893
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517
pubmed: 27768242
J Clin Aesthet Dermatol. 2016 Sep;9(9):43-48
pubmed: 27878061
J Am Acad Dermatol. 2017 Aug;77(2):310-317.e1
pubmed: 28416342
Scand J Gastroenterol. 1997 Sep;32(9):920-4
pubmed: 9299672
Gastroenterology. 1976 Nov;71(5):738-42
pubmed: 964567